Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
UNIVERSIDAD DE NAVARRA currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single action is assigned to 1 distinct examiner, CHEN, STACY BROWN, and is located within 1 distinct art unit. This concentration indicates a highly focused prosecution footprint for the company's current filings.
CHEN, STACY BROWN is the busiest examiner for the portfolio, holding 1 busiest examiner pending office action. This figure matches the total of 1 pending office action reported for the company. Because there is only 1 distinct examiner and 1 distinct art unit, the interaction with the patent office is streamlined under a single point of review.
The presence of 1 pending office action within the Biotechnology & Pharmaceuticals sector suggests a specific technical focus. With 1 distinct examiner and 1 distinct art unit involved, the company faces a singular administrative path. This 1 busiest examiner pending action managed by CHEN, STACY BROWN defines the current scope of prosecution for UNIVERSIDAD DE NAVARRA.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHEN, STACY BROWN | 1 | 66.1% | +40.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18557339 | USE OF ONCOLYTIC ADENOVIRUS FOR THE TREATMENT OF PEDIATRIC BRAIN CANCER | CHEN, STACY BROWN | — |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18557339 | USE OF ONCOLYTIC ADENOVIRUS FOR THE TREATMENT OF PEDIATRIC BRAIN CANCER | CHEN, STACY BROWN | 1672 | §112 | Non-Final OA | — | Pending | Oct 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial